APOBEC3B: a natural defender against viral infections
Role of APOBEC3B in the Innate Immune Response
This project looks at how the APOBEC3B protein helps cells stop viruses such as SARS‑CoV‑2 and what that could mean for people facing viral infections.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California-Irvine NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project ID | NIH-11252621 on NIH RePORTER |
What this research studies
Researchers will study the APOBEC3B protein inside cells using laboratory models and viral samples to see how it blocks viruses. They will compare ways the protein edits viral genetic material with other non‑editing actions that might protect cells. Experiments will map which parts of the protein are responsible and measure how those actions change viral replication and cell survival. The goal is to understand mechanisms that could be used to strengthen natural antiviral defenses.
Who could benefit from this research
Good fit: People who have had COVID‑19 or other viral respiratory infections, or who are willing to donate blood or tissue samples for laboratory research, would be the most relevant participants or sample donors.
Not a fit: Patients seeking an immediate new treatment are unlikely to benefit directly because this is laboratory basic science rather than a clinical therapy trial.
Why it matters
Potential benefit: If successful, the work could point to new antiviral approaches or ways to boost the body’s own defenses against viruses like COVID‑19.
How similar studies have performed: Previous studies show APOBEC enzymes can create mutations that block viruses like HIV and SARS‑CoV‑2, but the non‑mutation antiviral mechanisms this project focuses on are less explored and more novel.
Where this research is happening
Irvine, United States
- University of California-Irvine — Irvine, United States (Active)
Researchers
- Principal investigator: Buisson, Remi — University of California-Irvine
- Study coordinator: Buisson, Remi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.